Enzalutamide (formerly MDV3100; Medivation and Astellas) appears poised to become the fourth drug approved by the U.S. Food and Drug Administration for castration-resistant prostate cancer after chemotherapy, based on a phase III trial reported in the New England Journal of Medicine in August.

©2012 American Association for Cancer Research.
2012
You do not currently have access to this content.